Physician profile

Matthew Jones

Cardiovascular Disease · Brooklyn, NY

NPI 1104052570

$21,683.85

in general payments reported to CMS, 2019-2025

42 companies · $4,117 in 2025

The $4,117 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,454.91
Consulting Fee$4,290.00
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$3,570.00
Travel and Lodging$1,388.55
Education$135.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $4,185.45 2019-2025 Amvuttra
E.R. Squibb & Sons, L.L.C. $3,386.64 2020-2025 Camzyos
Novartis Pharmaceuticals Corporation $1,813.03 2019-2025
Medtronic Vascular, INC. $1,753.95 2019-2020
Boston Scientific Corporation $1,640.08 2019-2025 Avvigo Guidance System, Watchman Flx, Watchman Access System
Abbott Laboratories $1,604.60 2020-2024 Aveir, Jot Dx
Cook Medical LLC $931.38 2019-2024 Zilver Vena, Zilver Ptx
Boehringer Ingelheim Pharmaceuticals, INC. $643.16 2019-2025 Jardiance
Cardiovascular Systems INC. $597.79 2019-2021
Janssen Pharmaceuticals, INC $569.65 2019-2024 Xarelto
Amgen INC. $543.72 2019-2025 Repatha, Repatha
Shockwave Medical, INC $524.18 2019-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Astrazeneca Pharmaceuticals LP $518.20 2019-2024 Farxiga
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $499.50 2019-2025 Lifevest
Merck Sharp & Dohme LLC $454.90 2021-2024 Verquvo
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $253.98 2021-2024 Linq II, Corevalve Evolut R
Pfizer INC. $219.29 2019-2025
Biotronik INC. $182.29 2019-2024 Biomonitor
Asahi Intecc USA, INC. $169.65 2019-2023 Asahi Ptca Guide Wire
Actelion Pharmaceuticals US, INC. $156.37 2022-2023 Opsumit, Uptravi
Abiomed $123.29 2019-2024 Impella
Amarin Pharma, INC. $100.63 2019-2022
Bayer Healthcare Pharmaceuticals INC. $95.30 2024
Bridgebio Pharma, INC. $87.96 2025 Attruby
Kestra Medical Technology Services, INC. $79.91 2024-2025 Assure Wcd
Ge Healthcare $64.11 2021
Kiniksa Pharmaceuticals International, Plc $63.01 2024 Arcalyst
Tactile Systems Technology INC $51.65 2025 Nimbl, Flexitouch Plus
Glaxosmithkline, LLC. $50.08 2023-2025 Shingrix, Pediarix, Bexsero
Cagent Vascular INC $47.32 2023 Serrantor
Akcea Therapeutics, INC. $38.11 2019
Philips North America LLC $36.07 2022
Lilly USA, LLC $34.58 2019-2020
Baxter Healthcare $32.01 2023 Hillrom - Cardiac Ambulatory Monitor
Lexicon Pharmaceuticals, INC. $22.94 2023 Inpefa
Vifor Pharma, INC. $22.19 2021
Viiv Healthcare Company $21.59 2022
Bolton Medical INC $21.18 2019
Smith+Nephew, INC. $15.69 2024 Collagenase Santyl
Chiesi USA, INC. $14.87 2023 Kengreal
Qorumpartners $10.22 2022
Venclose INC. $3.33 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Jones

$21,683.85

in general payments reported 2019-2025

Years
2019-2025
Top company
Alnylam Pharmaceuticals INC.
Context
The $4,117 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/1383036/matthew-jones

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.